Global Hyperimmune Globulins Market Growth 2024-2030

Publication ID:

LPI01240660

Publication Date:

January 4, 2024

Pages:

109

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Hyperimmune Globulins market size was valued at US$ 1656.2 million in 2023. With growing demand in downstream market, the Hyperimmune Globulins is forecast to a readjusted size of US$ 2705.3 million by 2030 with a CAGR of 7.3% during review period.
The research report highlights the growth potential of the global Hyperimmune Globulins market. Hyperimmune Globulins are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Hyperimmune Globulins. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Hyperimmune Globulins market.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%.
Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent.
In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.
Key Features:
The report on Hyperimmune Globulins market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Hyperimmune Globulins market. It may include historical data, market segmentation by Type (e.g., Hepatitis B Immunoglobulins, Rabies Immunoglobulins), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Hyperimmune Globulins market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Hyperimmune Globulins market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Hyperimmune Globulins industry. This include advancements in Hyperimmune Globulins technology, Hyperimmune Globulins new entrants, Hyperimmune Globulins new investment, and other innovations that are shaping the future of Hyperimmune Globulins.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Hyperimmune Globulins market. It includes factors influencing customer ' purchasing decisions, preferences for Hyperimmune Globulins product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Hyperimmune Globulins market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Hyperimmune Globulins market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Hyperimmune Globulins market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Hyperimmune Globulins industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Hyperimmune Globulins market.
Market Segmentation:
Hyperimmune Globulins market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Segmentation by application
Government Institutions
Private Sector
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hyperimmune Globulins market?
What factors are driving Hyperimmune Globulins market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hyperimmune Globulins market opportunities vary by end market size?
How does Hyperimmune Globulins break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hyperimmune Globulins Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Hyperimmune Globulins by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Hyperimmune Globulins by Country/Region, 2019, 2023 & 2030
2.2 Hyperimmune Globulins Segment by Type
2.2.1 Hepatitis B Immunoglobulins
2.2.2 Rabies Immunoglobulins
2.2.3 Tetanus Immunoglobulins
2.2.4 Rho(D) Immunoglobulins
2.2.5 Other
2.3 Hyperimmune Globulins Sales by Type
2.3.1 Global Hyperimmune Globulins Sales Market Share by Type (2019-2024)
2.3.2 Global Hyperimmune Globulins Revenue and Market Share by Type (2019-2024)
2.3.3 Global Hyperimmune Globulins Sale Price by Type (2019-2024)
2.4 Hyperimmune Globulins Segment by Application
2.4.1 Government Institutions
2.4.2 Private Sector
2.4.3 Other
2.5 Hyperimmune Globulins Sales by Application
2.5.1 Global Hyperimmune Globulins Sale Market Share by Application (2019-2024)
2.5.2 Global Hyperimmune Globulins Revenue and Market Share by Application (2019-2024)
2.5.3 Global Hyperimmune Globulins Sale Price by Application (2019-2024)
3 Global Hyperimmune Globulins by Company
3.1 Global Hyperimmune Globulins Breakdown Data by Company
3.1.1 Global Hyperimmune Globulins Annual Sales by Company (2019-2024)
3.1.2 Global Hyperimmune Globulins Sales Market Share by Company (2019-2024)
3.2 Global Hyperimmune Globulins Annual Revenue by Company (2019-2024)
3.2.1 Global Hyperimmune Globulins Revenue by Company (2019-2024)
3.2.2 Global Hyperimmune Globulins Revenue Market Share by Company (2019-2024)
3.3 Global Hyperimmune Globulins Sale Price by Company
3.4 Key Manufacturers Hyperimmune Globulins Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hyperimmune Globulins Product Location Distribution
3.4.2 Players Hyperimmune Globulins Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Hyperimmune Globulins by Geographic Region
4.1 World Historic Hyperimmune Globulins Market Size by Geographic Region (2019-2024)
4.1.1 Global Hyperimmune Globulins Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Hyperimmune Globulins Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Hyperimmune Globulins Market Size by Country/Region (2019-2024)
4.2.1 Global Hyperimmune Globulins Annual Sales by Country/Region (2019-2024)
4.2.2 Global Hyperimmune Globulins Annual Revenue by Country/Region (2019-2024)
4.3 Americas Hyperimmune Globulins Sales Growth
4.4 APAC Hyperimmune Globulins Sales Growth
4.5 Europe Hyperimmune Globulins Sales Growth
4.6 Middle East & Africa Hyperimmune Globulins Sales Growth
5 Americas
5.1 Americas Hyperimmune Globulins Sales by Country
5.1.1 Americas Hyperimmune Globulins Sales by Country (2019-2024)
5.1.2 Americas Hyperimmune Globulins Revenue by Country (2019-2024)
5.2 Americas Hyperimmune Globulins Sales by Type
5.3 Americas Hyperimmune Globulins Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hyperimmune Globulins Sales by Region
6.1.1 APAC Hyperimmune Globulins Sales by Region (2019-2024)
6.1.2 APAC Hyperimmune Globulins Revenue by Region (2019-2024)
6.2 APAC Hyperimmune Globulins Sales by Type
6.3 APAC Hyperimmune Globulins Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Hyperimmune Globulins by Country
7.1.1 Europe Hyperimmune Globulins Sales by Country (2019-2024)
7.1.2 Europe Hyperimmune Globulins Revenue by Country (2019-2024)
7.2 Europe Hyperimmune Globulins Sales by Type
7.3 Europe Hyperimmune Globulins Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Hyperimmune Globulins by Country
8.1.1 Middle East & Africa Hyperimmune Globulins Sales by Country (2019-2024)
8.1.2 Middle East & Africa Hyperimmune Globulins Revenue by Country (2019-2024)
8.2 Middle East & Africa Hyperimmune Globulins Sales by Type
8.3 Middle East & Africa Hyperimmune Globulins Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hyperimmune Globulins
10.3 Manufacturing Process Analysis of Hyperimmune Globulins
10.4 Industry Chain Structure of Hyperimmune Globulins
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Hyperimmune Globulins Distributors
11.3 Hyperimmune Globulins Customer
12 World Forecast Review for Hyperimmune Globulins by Geographic Region
12.1 Global Hyperimmune Globulins Market Size Forecast by Region
12.1.1 Global Hyperimmune Globulins Forecast by Region (2025-2030)
12.1.2 Global Hyperimmune Globulins Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Hyperimmune Globulins Forecast by Type
12.7 Global Hyperimmune Globulins Forecast by Application
13 Key Players Analysis
13.1 CSL Behring
13.1.1 CSL Behring Company Information
13.1.2 CSL Behring Hyperimmune Globulins Product Portfolios and Specifications
13.1.3 CSL Behring Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 CSL Behring Main Business Overview
13.1.5 CSL Behring Latest Developments
13.2 Grifols
13.2.1 Grifols Company Information
13.2.2 Grifols Hyperimmune Globulins Product Portfolios and Specifications
13.2.3 Grifols Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Grifols Main Business Overview
13.2.5 Grifols Latest Developments
13.3 Biotest
13.3.1 Biotest Company Information
13.3.2 Biotest Hyperimmune Globulins Product Portfolios and Specifications
13.3.3 Biotest Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Biotest Main Business Overview
13.3.5 Biotest Latest Developments
13.4 Kedrion
13.4.1 Kedrion Company Information
13.4.2 Kedrion Hyperimmune Globulins Product Portfolios and Specifications
13.4.3 Kedrion Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Kedrion Main Business Overview
13.4.5 Kedrion Latest Developments
13.5 CBPO
13.5.1 CBPO Company Information
13.5.2 CBPO Hyperimmune Globulins Product Portfolios and Specifications
13.5.3 CBPO Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 CBPO Main Business Overview
13.5.5 CBPO Latest Developments
13.6 Emergent (Cangene)
13.6.1 Emergent (Cangene) Company Information
13.6.2 Emergent (Cangene) Hyperimmune Globulins Product Portfolios and Specifications
13.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Emergent (Cangene) Main Business Overview
13.6.5 Emergent (Cangene) Latest Developments
13.7 Kamada
13.7.1 Kamada Company Information
13.7.2 Kamada Hyperimmune Globulins Product Portfolios and Specifications
13.7.3 Kamada Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Kamada Main Business Overview
13.7.5 Kamada Latest Developments
13.8 CNBG
13.8.1 CNBG Company Information
13.8.2 CNBG Hyperimmune Globulins Product Portfolios and Specifications
13.8.3 CNBG Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 CNBG Main Business Overview
13.8.5 CNBG Latest Developments
13.9 Hualan Bio
13.9.1 Hualan Bio Company Information
13.9.2 Hualan Bio Hyperimmune Globulins Product Portfolios and Specifications
13.9.3 Hualan Bio Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Hualan Bio Main Business Overview
13.9.5 Hualan Bio Latest Developments
13.10 Shanghai RAAS
13.10.1 Shanghai RAAS Company Information
13.10.2 Shanghai RAAS Hyperimmune Globulins Product Portfolios and Specifications
13.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shanghai RAAS Main Business Overview
13.10.5 Shanghai RAAS Latest Developments
13.11 Sichuan Yuanda Shuyang
13.11.1 Sichuan Yuanda Shuyang Company Information
13.11.2 Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolios and Specifications
13.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Sichuan Yuanda Shuyang Main Business Overview
13.11.5 Sichuan Yuanda Shuyang Latest Developments
13.12 ADMA Biologics
13.12.1 ADMA Biologics Company Information
13.12.2 ADMA Biologics Hyperimmune Globulins Product Portfolios and Specifications
13.12.3 ADMA Biologics Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 ADMA Biologics Main Business Overview
13.12.5 ADMA Biologics Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂